We're taking a closer look at Cyclacel Pharmaceuticals today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 1.0% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.
-
Cyclacel Pharmaceuticals has moved -69.9% over the last year compared to -1.4% for the S&P 500 -- a difference of -69.0%
-
CYCC has an average analyst rating of buy and is -95.89% away from its mean target price of $13.5 per share
-
Its trailing 12 month earnings per share (EPS) is $-2.01
-
Cyclacel Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -0.3 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $-2.89 and its forward P/E ratio is -0.2
-
The company has a Price to Book (P/B) ratio of 0.45 in contrast to the S&P 500's average ratio of 2.95
-
Cyclacel Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Cyclacel Pharmaceuticals has on average reported free cash flows of $-14222000.0 over the last four years, during which time they have grown by an an average of -21.8%
